Inducement grants include stock options to purchase 90,750 common shares, awarded to three newly hired non-executive employees
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has granted equity inducement awards to three newly hired non-executive employees. The awards consist of options to purchase an aggregate of 90,750 common shares of the Company (the “Options”). The effective grant date for these awards is November 3, 2025.
The Options were granted as an inducement to each employee entering into employment with MindMed in accordance with Nasdaq Listing Rule 5635(c)(4). The Company’s Compensation Committee of the Board of Directors approved the grants on October 31, 2025. These awards were made outside of MindMed’s existing equity incentive plans and were structured to attract and retain top-tier talent as the Company continues to advance its late-stage development pipeline and expand its operational capabilities.
Grant Terms and Vesting Schedule
Each Option has an exercise price equal to the closing price of MindMed’s common shares on the Nasdaq Global Market on the date of grant. The Options will vest over a four-year period, designed to align the interests of employees with those of the Company’s shareholders and to encourage long-term value creation.
Specifically, 25% of each employee’s Options will vest on the first anniversary of the grant date, with the remaining 75% vesting in substantially equal monthly installments over the following three years. The vesting of the awards is contingent upon the individual’s continued employment with the Company through the applicable vesting dates.
This structure reflects industry-standard practices and underscores MindMed’s commitment to offering competitive compensation packages that combine salary, performance incentives, and long-term equity participation. The Company believes this approach is critical to attracting experienced professionals in the highly competitive biopharmaceutical sector.
Commitment to Talent and Growth
The addition of new employees across MindMed’s scientific, clinical, and operational functions supports the Company’s strategic priorities as it advances multiple late-stage clinical programs targeting serious brain health disorders. These new hires bring specialized expertise across drug development, regulatory strategy, and commercial planning—areas essential to MindMed’s long-term growth trajectory.
“MindMed continues to strengthen its team with exceptional talent as we progress toward key milestones in our development programs,” said Robert Barrow, Chief Executive Officer and Director of MindMed. “Our mission to transform the treatment of brain health disorders requires a combination of scientific innovation and operational excellence. These inducement grants reflect our ongoing commitment to reward employees who share our vision and to align their success with the success of our shareholders.”
Strategic Rationale for Inducement Grants
MindMed utilizes inducement equity grants as a key component of its recruitment strategy, particularly when hiring individuals with unique expertise or leadership experience in neuroscience, clinical development, and regulatory affairs. The inducement grants provide immediate equity incentives to attract high-caliber talent while preserving the remaining capacity of the Company’s shareholder-approved equity incentive plans.
Under Nasdaq Listing Rule 5635(c)(4), inducement awards may be granted to new employees as a material component of their employment agreement without the need for prior shareholder approval. Such awards are typically used by growth-stage biotechnology companies to accelerate the hiring of top professionals who can immediately contribute to clinical and corporate goals.
MindMed’s Compensation Committee carefully reviews each inducement grant to ensure that the terms are consistent with the Company’s compensation philosophy, market benchmarks, and shareholder interests. The Committee also ensures that all grants comply with applicable securities laws and Nasdaq listing standards.
Advancing a Leading Portfolio in Brain Health
MindMed is advancing a robust clinical-stage pipeline designed to address unmet needs across a range of brain health disorders. The Company’s investigational candidates leverage both classic and next-generation psychedelic compounds as well as non-psychedelic mechanisms to improve patient outcomes in conditions such as anxiety, depression, and substance use disorders.
MindMed’s lead product candidate, MM-120 (lysergide D-tartrate), is currently being evaluated in a Phase 3 clinical program for the treatment of generalized anxiety disorder (GAD). The program builds upon the strong efficacy and safety results observed in the Company’s Phase 2b study, which demonstrated statistically significant and clinically meaningful reductions in anxiety symptoms. The Company also continues to advance MM-402, a novel R-MDMA compound in Phase 1 evaluation for autism spectrum disorder (ASD), as part of its broader commitment to addressing diverse neuropsychiatric conditions.
With multiple programs in advanced stages of development and a growing body of clinical evidence supporting its approach, MindMed remains focused on building the organizational foundation necessary to successfully execute its clinical and regulatory strategy.
Strengthening Organizational Capabilities
As MindMed transitions toward potential commercialization of its late-stage assets, the Company has been expanding key teams in clinical operations, quality assurance, medical affairs, and commercial planning. These functions are critical as the Company prepares for regulatory submissions and potential market introductions in the coming years.
The new employees receiving inducement grants are expected to play integral roles in executing MindMed’s development and operational priorities. The Company’s leadership believes that offering equity-based compensation fosters a culture of ownership and accountability while enhancing employee engagement and retention.
“Equity ownership is an essential element of our culture at MindMed,” added Barrow. “It ensures that every team member—from the bench scientist to the senior leader—shares in the responsibility and the rewards of advancing our mission to improve the lives of people struggling with brain health disorders
About MindMed
MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.
source link: https://www.businesswire.com